Table 4 Cardiac, clinical and global outcomes
From: Management and outcome of patients supported with Impella 5.0 for refractory cardiogenic shock
Event | Total (n = 40) |
|---|---|
Death during Impella 5.0 support, n (%) | 12 (30) |
Impella 5.0 weaning, n (%) | 18 (45) |
Sustained cardiac recoverya at ICU discharge, n (%) | 16 (40) |
Bridge to LVAD, n (%) | 9 (23) |
Bridge to heart transplantation, n (%) | 3 (8) |
Total MV duration, days [IQR] | 15 [7–26] |
Need for RRT in ICU, n (%) | 17 (43) |
ICU length of stay, days [IQR] | 20 [8–32] |
Mortality at day 28, n (%) | 14 (35) |
 Post-AMI, n (%) | 9 (53 %) |
 Dilated cardiomyopathy, n (%) | 3 (25 %) |
 Postcardiotomy, n (%) | 1 (14 %) |
 Others, n (%) | 1 (25 %) |
Mortality at ICU discharge, n (%) | 17 (43) |
Mortality at month 6, n (%) | 20 (50) |